Pliant Therapeutics Inc. (PLRX) News
Filter PLRX News Items
PLRX News Results
|Loading, please wait...|
PLRX News Highlights
- For PLRX, its 30 day story count is now at 5.
- Over the past 17 days, the trend for PLRX's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- MG and LUNG are the most mentioned tickers in articles about PLRX.
Latest PLRX News From Around the Web
Below are the latest news stories about Pliant Therapeutics Inc that investors may wish to consider to help them evaluate PLRX as an investment opportunity.
Pliant Therapeutics (NASDAQ:PLRX) said that following a positive independent safety review, enrollment has begun in a phase 2a trial of PLN-74809 at 320 mg dose in patients with idiopathic pulmonary fibrosis (IPF), a type of lung disease. The independent Data Safety Monitoring Board review recommended the phase 2a trial, dubbed INTEGRIS-IPF, continue...
Pliant Therapeutics Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-IPF Phase 2a trial continue without modification and proceed to evaluate dosing at 320mg Trial initiation follows the FDA authorization of evaluation of long-term dosing of PLN-74809 at doses up to 320 mg in IPF patients SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel
Pliant Therapeutics (NASDAQ:PLRX) investors are sitting on a loss of 69% if they invested a year ago
Even the best stock pickers will make plenty of bad investments. Unfortunately, shareholders of Pliant Therapeutics...
Pliant Therapeutics Highlights Recent Developments for Lead Program PLN-74809 and Expected 2022 Milestones
Enrollment complete in INTERGRIS-IPF Phase 2a clinical trial with top-line data expected mid-2022 FDA has authorized evaluation of long-term treatment with PLN-74809 at doses up to 320 mg in IPF Company will present updates at the 40th Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of
SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant, will present a company update as part of the 40th Annual J.P Morgan Healthcare Conference. The virtual presentation will begin on Wednesday, January 12, 2022, at 9:45 a.
Heading into year’s end, the Street’s professional analysts are busy putting together their predictive models, working to give investors an idea just where the markets are heading. All in all, it would seem to be a positive picture; despite some recent volatility, the markets are still following the sustained upward trend they’ve been on since the spring of last year. Writing from Oppenheimer, chief investment strategist John Stoltzfus leads the bulls. He sees gains of 13% in store for the S&P 5
Pliant Therapeutics, Inc. (NASDAQ:PLRX) shares gapped up before the market opened on Friday . The stock had previously closed at $14.22, but opened at $15.57. Pliant Therapeutics shares last traded at $14.95, with a volume of 745 shares trading hands. PLRX has been the subject of a number of research reports. Zacks Investment Research cut 
Zacks Investment Research cut shares of Pliant Therapeutics (NASDAQ:PLRX) from a hold rating to a sell rating in a research report report published on Monday, Zacks.com reports. According to Zacks, Pliant Therapeutics Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing novel therapies for the treatment of fibrosis. The companys 
In this article, we discuss the 10 pharmaceutical stocks to buy under $20 according to Jeremy Green’s Redmile Group portfolio based on Q3 holdings of the fund. If you want to skip our detailed analysis of Green’s history, investment philosophy, and hedge fund performance, go directly to the 5 Pharmaceutical Stocks to Buy Under $20 According […]